News headlines about Apollo Endosurgery (NASDAQ:APEN) have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.9645643495478 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Apollo Endosurgery from a “buy” rating to a “hold” rating in a report on Wednesday, December 27th. ValuEngine upgraded shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Northland Securities reiterated a “buy” rating and set a $12.00 target price on shares of Apollo Endosurgery in a research report on Tuesday, November 28th. Finally, Roth Capital set a $10.00 target price on shares of Apollo Endosurgery and gave the stock a “buy” rating in a research report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $9.44.
Shares of Apollo Endosurgery (APEN) traded down $0.10 during trading on Monday, reaching $5.60. 42,190 shares of the company’s stock traded hands, compared to its average volume of 57,087. Apollo Endosurgery has a twelve month low of $3.55 and a twelve month high of $14.09. The company has a market capitalization of $98.56, a price-to-earnings ratio of -0.15 and a beta of 0.57. The company has a current ratio of 2.54, a quick ratio of 2.00 and a debt-to-equity ratio of 0.58.
In other Apollo Endosurgery news, major shareholder Stonepine Capital, L.P. purchased 45,434 shares of the firm’s stock in a transaction on Wednesday, December 20th. The shares were purchased at an average cost of $4.50 per share, with a total value of $204,453.00. Following the completion of the purchase, the insider now owns 2,410,141 shares of the company’s stock, valued at approximately $10,845,634.50. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Bret Schwartzhoff purchased 9,500 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were acquired at an average cost of $4.24 per share, for a total transaction of $40,280.00. Following the completion of the purchase, the vice president now directly owns 15,631 shares of the company’s stock, valued at approximately $66,275.44. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 273,386 shares of company stock valued at $1,328,331. 74.20% of the stock is currently owned by company insiders.
WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-apollo-endosurgery-apen-stock-price.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.